Skip to Content

BiovaxID Approval Status

  • FDA approved: No
  • Brand name: BiovaxID
  • Company: Biovest International, Inc.
  • Treatment for: Non-Hodgkin's Lymphoma

BiovaxID is a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma.

Development Status and FDA Approval Process for BiovaxID

Jun 22, 2010Biovest Announces Mantle Cell Lymphoma as Next Target Indication for Personalized Cancer Vaccine
Jun  5, 2007Biovest to File for Accelerated Conditional Approval of BiovaxID
Feb 22, 2006Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID, a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.